Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans
Kaasinen, Eevi; Kuismin, Outi; Rajamäki, Kristiina; Ristolainen, Heikki; Aavikko, Mervi; Kondelin, Johanna; Saarinen, Silva; Berta, Davide G.; Katainen, Riku; Hirvonen, Elina A. M.; Karhu, Auli; Taira, Aurora; Tanskanen, Tomas; Alkodsi, Amjad; Taipale, Minna; Morgunova, Ekaterina; Franssila, Kaarle; Lehtonen, Rainer; Mäkinen, Markus; Aittomäki, Kristiina; Palotie, Aarno; Kurki, Mitja I.; Pietiläinen, Olli; Hilpert, Morgane; Saarentaus, Elmo; Niinimäki, Jaakko; Junttila, Juhani; Kaikkonen, Kari; Vahteristo, Pia; Skoda, Radek C.; Seppänen, Mikko R. J.; Eklund, Kari K.; Taipale, Jussi; Kilpivaara, Outi; Aaltonen, Lauri A. (2019-03-19)
Kaasinen, E., Kuismin, O., Rajamäki, K., Ristolainen, H., Aavikko, M., Kondelin, J., … Aaltonen, L. A. (2019). Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-09198-7
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
https://creativecommons.org/licenses/by/4.0/
https://urn.fi/URN:NBN:fi-fe2019092529684
Tiivistelmä
Abstract
Clonal hematopoiesis driven by somatic heterozygous TET2 loss is linked to malignant degeneration via consequent aberrant DNA methylation, and possibly to cardiovascular disease via increased cytokine and chemokine expression as reported in mice. Here, we discover a germline TET2 mutation in a lymphoma family. We observe neither unusual predisposition to atherosclerosis nor abnormal pro-inflammatory cytokine or chemokine expression. The latter finding is confirmed in cells from three additional unrelated TET2 germline mutation carriers. The TET2 defect elevates blood DNA methylation levels, especially at active enhancers and cell-type specific regulatory regions with binding sequences of master transcription factors involved in hematopoiesis. The regions display reduced methylation relative to all open chromatin regions in four DNMT3A germline mutation carriers, potentially due to TET2-mediated oxidation. Our findings provide insight into the interplay between epigenetic modulators and transcription factor activity in hematological neoplasia, but do not confirm the putative role of TET2 in atherosclerosis.
Kokoelmat
- Avoin saatavuus [31987]